Vα24-invariant NKT cells inhibit tumor growth by targeting tumor-associated macrophages (TAMs). Tumor progression therefore requires that TAMs evade NKT cell activity through yet-unknown mechanisms. Here we report that a subset of cells in neuroblastoma (NB) cell lines and primary tumors expresses membrane-bound TNF-α (mbTNF-α). These proinflammatory tumor cells induced production of the chemokine CCL20 from TAMs via activation of the NF-κB signaling pathway, an effect that was amplified in hypoxia. Flow cytometry analyses of human primary NB tumors revealed selective accumulation of CCL20 in TAMs. Neutralization of the chemokine inhibited in vitro migration of NKT cells toward tumor-conditioned hypoxic monocytes and localization of NKT cells to NB grafts in mice. We also found that hypoxia impaired NKT cell viability and function. Thus, CCL20-producing TAMs served as a hypoxic trap for tumor-infiltrating NKT cells. IL-15 protected antigen-activated NKT cells from hypoxia, and transgenic expression of IL-15 in adoptively transferred NKT cells dramatically enhanced their antimetastatic activity in mice. Thus, tumor-induced chemokine production in hypoxic TAMs and consequent chemoattraction and inhibition of NKT cells represents a mechanism of immune escape that can be reversed by adoptive immunotherapy with IL-15–transduced NKT cells.
Daofeng Liu, Liping Song, Jie Wei, Amy N. Courtney, Xiuhua Gao, Ekaterina Marinova, Linjie Guo, Andras Heczey, Shahab Asgharzadeh, Eugene Kim, Gianpietro Dotti, Leonid S. Metelitsa
Title and authors | Publication | Year |
---|---|---|
iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment
Zong J, Li YR |
Bioengineering | 2025 |
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, Zhu E, Tian Y, Huang J, Rezek V, Kitchen S, Hsiai T, Zhou JJ, Wang P, Chai-Ho W, Park S, Seet CS, Oliai C, Yang L |
Nature Communications | 2025 |
Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice
Zhenyu Dai, Zheng Zhu, Zhiyao Li, Lei Tian, Kun-Yu Teng, Hanyu Chen, Li-Shu Wang, Jianying Zhang, Laleh G Melstrom, Michael A. Caligiuri, Jianhua Yu |
Journal of Clinical Investigation | 2025 |
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function
Tian G, Barragan GA, Yu H, Martinez-Amador C, Adaikkalavan A, Rios X, Guo L, Drabek JM, Pardias O, Xu X, Montalbano A, Zhang C, Li Y, Courtney AN, Di Pierro EJ, Metelitsa LS |
Cancer Immunology Research | 2025 |
Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy
Li S, Li YR, Nan H, Liu Z, Fang Y, Zhu Y, Lyu Z, Shao Z, Zhu E, zhang B, Yang Y, Shen X, Chen Y, Hsiai T, Yang L |
Research Square | 2025 |
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, Dellabona P, Genovese P, Savoldo B, Metelitsa LS, Dotti G |
Nature Communications | 2024 |
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).
Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS, Carneiro BA |
Oncogene | 2024 |
T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells
Das R |
Critical Reviews in Oncogenesis | 2024 |
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method.
Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, Li Z, Yu Y, Dunn ZS, Guo W, Cen X, Husman T, Bajpai A, Kramer A, Wilson M, Fang Y, Huang J, Li S, Zhou Y, Zhang Y, Hahn Z, Zhu E, Ma F, Pan C, Lusis AJ, Zhou JJ, Seet CS, Kohn DB, Wang P, Zhou XJ, Pellegrini M, Puliafito BR, Larson SM, Yang L |
Nature Biotechnology | 2024 |
Deficiency and dysfunctional roles of natural killer T cells in patients with ARDS
Park KJ, Kim TO, Cho YN, Jin HM, Jo YG, Shin HJ, Kho BG, Kee SJ, Park YW |
Frontiers in Immunology | 2024 |
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.
Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, Weng J, Du X, Wu K, Lai P |
Journal of hematology & oncology | 2024 |
Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments
Wu X, Fang S |
Frontiers in Immunology | 2024 |
A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses
Shi W, Xu W, Song L, Zeng Q, Qi G, Qin Y, Li Z, Liu X, Jiao Z, Zhao Y, Liu N, Lu H |
Molecular Therapy | 2024 |
Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
Iyoda T, Yamasaki S, Ueda S, Shimizu K, Fujii SI |
Biomolecules | 2023 |
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma.
Tomolonis JA, Xu X, Dholakia KH, Zhang C, Guo L, Courtney AN, Wang S, Balzeau J, Barragán GA, Tian G, Di Pierro EJ, Metelitsa LS |
Journal for ImmunoTherapy of Cancer | 2023 |
PTBP2-Mediated Alternative Splicing of IRF9 Controls Tumor-Associated Monocyte/Macrophage Chemotaxis and Repolarization in Neuroblastoma Progression
Tang J, He J, Guo H, Lin H, Li M, Yang T, Wang HY, Li D, Liu J, Li L, Xia H, Zhuo Z, Miao L |
Research | 2023 |
New cell sources for CAR-based immunotherapy
Mazinani M, Rahbarizadeh F |
Biomarker Research | 2023 |
Advancing Cell-Based Cancer Immunotherapy Through Stem Cell Engineering
Li YR, Dunn ZS, Yu Y, Li M, Wang P, Yang L |
Cell Stem Cell | 2023 |
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS |
Nature Medicine | 2023 |
Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.
Maryam S, Krukiewicz K, Haq IU, Khan AA, Yahya G, Cavalu S |
Journal of Clinical Medicine | 2023 |
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR |
Cells | 2023 |
Primary Mouse Invariant Natural Killer T (iNKT) Cell Purification and Transduction
Delfanti G, Dellabona P, Casorati G |
Bio-protocol | 2023 |
Challenges and new technologies in adoptive cell therapy.
Zhang P, Zhang G, Wan X |
Journal of Hematology & Oncology | 2023 |
Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges
Zappa E, Vitali A, Anders K, Molenaar JJ, Wienke J, Künkele A |
European Journal of Cancer | 2023 |
Targeting the myeloid microenvironment in neuroblastoma.
Stip MC, Teeuwen L, Dierselhuis MP, Leusen JHW, Krijgsman D |
Journal of experimental & clinical cancer research : CR | 2023 |
iNKT: A new avenue for CAR-based cancer immunotherapy
Y Liu, G Wang, D Chai, Y Dang, J Zheng, H Li |
Translational oncology | 2022 |
The iNKT Cell–Macrophage Axis in Homeostasis and Disease
M Cruz, J Loureiro, M Oliveira, M Macedo |
International journal of molecular sciences | 2022 |
Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers
D Wu, X Liu, J Mu, J Yang, F Wu, H Zhou |
Biomolecules | 2022 |
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
Nelson A, Gebremeskel S, Lichty BD, Johnston B |
Journal for ImmunoTherapy of Cancer | 2022 |
Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment
Delfanti G, Dellabona P, Casorati G, Fedeli M |
Frontiers in Medicine | 2022 |
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SM, Rahbarizadeh F |
Frontiers in immunology | 2022 |
Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T, Yu SK, Xiang Y, Lu KH, Sun M |
Frontiers in immunology | 2022 |
Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.
Nguyen R, Zhang X, Sun M, Abbas S, Seibert C, Kelly MC, Shern JF, Thiele CJ |
Clinical cancer research | 2022 |
Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy
Courtney AN, Tian G, Metelitsa LS |
Blood | 2022 |
Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies
Quach DH, Lulla P, Rooney CM |
Blood | 2022 |
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
A Nelson, JD Lukacs, B Johnston |
Cancers | 2021 |
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
M Bell, S Gottschalk |
Frontiers in immunology | 2021 |
Low Expression of IL-15 and NKT in Tumor Microenvironment Predicts Poor Outcome of MYCN-Non-Amplified Neuroblastoma
YM Liao, TH Hung, JK Tung, J Yu, YL Hsu, JT Hung, AL Yu |
Journal of Personalized Medicine | 2021 |
Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: A comprehensive review
KT Jin, WL Du, HR Lan, YY Liu, CS Mao, JL Du, XZ Mou |
Cancer Science | 2021 |
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities
F Akter, B Simon, NL de Boer, N Redjal, H Wakimoto, K Shah |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2021 |
A Nanoradiomics Approach for Differentiation of Tumors Based on Tumor-Associated Macrophage Burden
Z Starosolski, AN Courtney, M Srivastava, L Guo, I Stupin, LS Metelitsa, A Annapragada, KB Ghaghada, AP Kostikov |
Contrast Media & Molecular Imaging | 2021 |
Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma
Y Yu, Y Zeng, X Xia, JG Zhou, F Cao |
Cancer control : journal of the Moffitt Cancer Center | 2021 |
Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
F Morandi, F Sabatini, M Podestà, I Airoldi |
Human vaccines | 2021 |
Artificial Tumor Microenvironments in Neuroblastoma
CH Quinn, AM Beierle, EA Beierle |
Cancers | 2021 |
A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy
H Xu, IN Buhtoiarov, H Guo, NK Cheung |
OncoImmunology | 2021 |
The role of NKT cells in gastrointestinal cancers
Burks J, Olkhanud PB, Berzofsky JA |
OncoImmunology | 2021 |
Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
KO McNerney, SA Karageorgos, MD Hogarty, H Bassiri |
Frontiers in immunology | 2020 |
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
A Heczey, AN Courtney, A Montalbano, S Robinson, K Liu, M Li, N Ghatwai, O Dakhova, B Liu, T Raveh-Sadka, CN Chauvin-Fleurence, X Xu, H Ngai, EJ Pierro, B Savoldo, G Dotti, LS Metelitsa |
Nature Medicine | 2020 |
IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA-CD62L+CD4+ Invariant NKT Cells With Th-2 Biased Cytokine Production Profile
A Trujillo-Ocampo, HW Cho, M Clowers, S Pareek, W Ruiz-Vazquez, SE Lee, JS Im |
Frontiers in immunology | 2020 |
“Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
KX Liu, S Joshi |
Frontiers in immunology | 2020 |
Tumor-Associated Macrophages: Protumoral Macrophages in Inflammatory Tumor Microenvironment
S Malekghasemi, J Majidi, A Baghbanzadeh, J Abdolalizadeh, B Baradaran, L Aghebati-Maleki |
Advanced pharmaceutical bulletin | 2020 |
Editorial: NKT Cells in Cancer Immunotherapy
TJ Webb, W Yuan, E Meyer, P Dellabona |
Frontiers in immunology | 2020 |
Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor
S Paul, S Chhatar, A Mishra, G Lal |
Journal for ImmunoTherapy of Cancer | 2019 |
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer
Y Zhu, DJ Smith, Y Zhou, YR Li, J Yu, D Lee, YC Wang, SD Biase, , C Hardoy, J Ku, T Tsao, LJ Lin, AT Pham, H Moon, J McLaughlin, D Cheng, RP Hollis, B Campo-Fernandez, F Urbinati, L Wei, L Pang, V Rezek, B Berent-Maoz, MH Macabali, D Gjertson, X Wang, Z Galic, SG Kitchen, DS An, S Hu-Lieskovan, PJ Kaplan-Lefko, SN Oliveira, CS Seet, SM Larson, SJ Forman, JR Heath, JA Zack, GM Crooks, CG Radu, A Ribas, DB Kohn, ON Witte, L Yang |
Cell Stem Cell | 2019 |
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
X Xu, W Huang, A Heczey, D Liu, L Guo, M Wood, J Jin, AN Courtney, B Liu, EJ Pierro, J Hicks, GA Barragan, H Ngai, Y Chen, B Savoldo, G Dotti, LS Metelitsa |
Clinical cancer research | 2019 |
Human cord blood (hCB)-CD34+ humanized mice fail to reject human acute myeloid leukemia cells
O Tanaskovic, MV Falzacappa, PG Pelicci, CH Kim |
PloS one | 2019 |
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
KC Pituch, J Miska, G Krenciute, WK Panek, G Li, T Rodriguez-Cruz, M Wu, Y Han, MS Lesniak, S Gottschalk, IV Balyasnikova |
Molecular Therapy | 2018 |
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
BJ Wolf, JE Choi, MA Exley |
Frontiers in immunology | 2018 |
Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment
CM Wunderlich, PJ Ackermann, AL Ostermann, P Adams-Quack, MC Vogt, ML Tran, A Nikolajev, A Waisman, C Garbers, S Theurich, J Mauer, N Hövelmeyer, FT Wunderlich |
Nature Communications | 2018 |
The Pathophysiological Relevance of the iNKT Cell/Mononuclear Phagocyte Crosstalk in Tissues
F Cortesi, G Delfanti, G Casorati, P Dellabona |
Frontiers in immunology | 2018 |
Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
T Vanichapol, S Chutipongtanate, U Anurathapan, S Hongeng |
BioMed Research International | 2018 |
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors
F Pohl-Guimarães, C Yang, KA Dyson, TJ Wildes, J Drake, J Huang, C Flores, EJ Sayour, DA Mitchell |
Molecular Therapy | 2018 |
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma
L Fultang, LD Gamble, L Gneo, AM Berry, SA Egan, FD Bie, O Yogev, GL Eden, S Booth, S Brownhill, A Vardon, CM McConville, PN Cheng, MD Norris, HC Etchevers, J Murray, DS Ziegler, L Chesler, R Schmidt, SA Burchill, M Haber, CD Santo, F Mussai |
Cancer research | 2018 |
Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis
SK Lee, KK Park, HJ Kim, J Park, SH Son, KR Kim, WY Chung |
Scientific Reports | 2017 |
Humanized Mouse Models of Clinical Disease
NC Walsh, LL Kenney, S Jangalwe, KE Aryee, DL Greiner, MA Brehm, LD Shultz |
Annual review of pathology | 2017 |
Tumor-associated macrophages: implications in cancer immunotherapy
AJ Petty, Y Yang |
Immunotherapy | 2017 |
Modeling Natural Killer Cell Targeted Immunotherapies
S Lopez-Lastra, JP di Santo |
Frontiers in immunology | 2017 |
Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies
PY Lam, MD Nissen, SR Mattarollo |
Frontiers in immunology | 2017 |
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
T Shum, B Omer, H Tashiro, RL Kruse, DL Wagner, K Parikh, Z Yi, T Sauer, D Liu, R Parihar, P Castillo, H Liu, MK Brenner, LS Metelitsa, S Gottschalk, CM Rooney |
Cancer Discovery | 2017 |
Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
M Bedard, M Salio, V Cerundolo |
Frontiers in immunology | 2017 |
Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges: Cytotoxic lymphocytes and atherosclerosis
T Kyaw, K Peter, Y Li, P Tipping, BH Toh, A Bobik |
British Journal of Pharmacology | 2017 |
Targeting O -Acetyl-GD2 Ganglioside for Cancer Immunotherapy
J Fleurence, S Fougeray, M Bahri, D Cochonneau, B Clémenceau, F Paris, A Heczey, S Birklé |
Journal of Immunology Research | 2017 |
IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer
K Rohena-Rivera, MM Sánchez-Vázquez, DA Aponte-Colón, IS Forestier-Román, ME Quintero-Aguiló, M Martínez-Ferrer, A Ahmad |
PloS one | 2017 |
Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation
T Zhang, Y Liu, X Peng, J Fan, Z Peng |
Disease Markers | 2017 |
Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
G Krenciute, BL Prinzing, Z Yi, MF Wu, H Liu, G Dotti, IV Balyasnikova, S Gottschalk |
Cancer immunology research | 2017 |
Human T effector cells are adapted to hypoxia through HIF1α and glycolytic metabolism
Yang Xu, Arindam Chaudhury, Ming Zhang, Barbara Savoldo, Leonid Metelitsa, John Rodgers, Jason Yustein, Joel Neilson, Gianpietro Dotti |
Journal of Clinical Investigation | 2016 |
Immunotherapeutic strategies targeting natural killer T cell responses in cancer
SC Shissler, DR Bollino, IV Tiper, JP Bates, R Derakhshandeh, TJ Webb |
Immunogenetics | 2016 |
Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression
P Guan, H Bassiri, NP Patel, KE Nichols, R Das |
Bone Marrow Transplantation | 2016 |
Tumor-infiltrating lymphocytes (TILs) from patients with glioma
Z Liu, Q Meng, J Bartek, T Poiret, O Persson, L Rane, E Rangelova, C Illies, IH Peredo, X Luo, MV Rao, RA Robertson, E Dodoo, M Maeurer |
OncoImmunology | 2016 |
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
AH Long, SL Highfill, Y Cui, JP Smith, AJ Walker, S Ramakrishna, R El-Etriby, S Galli, MG Tsokos, RJ Orentas, CL Mackall |
Cancer immunology research | 2016 |
Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia: Table 1
JS Brown |
Schizophrenia Bulletin | 2016 |
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity
F Mussai, S Egan, S Hunter, H Webber, J Fisher, R Wheat, C McConville, Y Sbirkov, K Wheeler, G Bendle, K Petrie, J Anderson, L Chesler, CD Santo |
Cancer research | 2015 |
Neuroblastoma: Molecular Pathogenesis and Therapy
CU Louis, JM Shohet |
Annual Review of Medicine | 2015 |
Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model
L Chakrabarti, C Morgan, AD Sandler, X Bai |
PloS one | 2015 |
Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32
Markus Maeurer, Martin Rao, Alimuddin Zumla |
Annals of translational medicine | 2015 |
Invariant Natural Killer T Cell Deficiency and Functional Impairment in Sleep Apnea: Links to Cancer Comorbidity
G Gaoatswe, BD Kent, MA Corrigan, G Nolan, AE Hogan, WT McNicholas, D O'Shea |
Sleep | 2015 |
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
K Pilipow, A Roberto, M Roederer, TA Waldmann, D Mavilio, E Lugli |
Cancer research | 2015 |
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
Andras Heczey, Daofeng Liu, Gengwen Tian, Amy N Courtney, Jie Wei, Ekaterina Marinova, Xiuhua Gao, Linjie Guo, Eric Yvon, John Hicks, Hao Liu, Gianpietro Dotti, Leonid S Metelitsa |
Blood | 2014 |
Mechanisms Driving Macrophage Diversity and Specialization in Distinct Tumor Microenvironments and Parallelisms with Other Tissues
EV Overmeire, D Laoui, J Keirsse, JA van Ginderachter, A Sarukhan |
Frontiers in immunology | 2014 |
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases
M Terabe, JA Berzofsky |
Cancer Immunology, Immunotherapy | 2014 |
Human Cancer Growth and Therapy in Immunodeficient Mouse Models
LD Shultz, N Goodwin, F Ishikawa, V Hosur, BL Lyons, DL Greiner |
Cold Spring Harbor Protocols | 2014 |
Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
E Gomes-Giacoia, M Miyake, S Goodison, A Sriharan, G Zhang, L You, JO Egan, PR Rhode, AS Parker, KX Chai, HC Wong, CJ Rosser |
PloS one | 2014 |
GD2-Targeted Immunotherapy and Radioimmunotherapy
K Dobrenkov, NK Cheung |
Seminars in Oncology | 2014 |
The tumor microenvironment: a pitch for multiple players
G Schiavoni, L Gabriele, F Mattei |
Frontiers in Oncology | 2013 |
Immunosuppressive microenvironment in neuroblastoma
V Pistoia, F Morandi, G Bianchi, A Pezzolo, I Prigione, L Raffaghello |
Frontiers in Oncology | 2013 |
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
NK Cheung, MA Dyer |
Nature Reviews Cancer | 2013 |
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals
C Arber, H Abhyankar, HE Heslop, MK Brenner, H Liu, G Dotti, B Savoldo |
Gene Therapy | 2013 |
Differential expression and TNF-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas
JL Oliver, MP Alexander, AG Norrod, IM Mullins, DW Mullins |
Pigment Cell & Melanoma Research | 2013 |